Intriguingly, Kanesaka et al. previously reported that MMP-3 serum levels were higher during the relapsing stage of MS than in remission [27], implicating MMP-3 as a molecular biomarker for the acute phase of inflammatory demyelination. The gene discussed is MMP3; the disease is myeloid sarcoma.